Association	0	10
of	12	13
mutation	15	22
patterns	24	31
in	33	34
GyrA	36	39
and	41	43
ParC	45	48
genes	50	54
with	56	59
quinolone	61	69
resistance	71	80
levels	82	87
in	89	90
lactic	92	97
acid	99	102
bacteria	104	111
.	112	112

The	114	116
quinolone	118	126
resistance	128	137
of	139	140
19	142	143
lactic	145	150
acid	152	155
bacterial	157	165
strains	167	173
belonging	175	183
to	185	186
the	188	190
genera	192	197
Enterococcus	199	210
and	212	214
Lactobacillus	216	228
isolated	230	237
from	239	242
the	244	246
natural	248	254
fermented	256	264
koumiss	266	272
and	274	276
yoghurt	278	284
were	286	289
investigated	291	302
.	303	303

The	305	307
objective	309	317
of	319	320
this	322	325
study	327	331
was	333	335
to	337	338
determine	340	348
the	350	352
quinolone	354	362
resistance	364	373
levels	375	380
and	382	384
to	386	387
explore	389	395
the	397	399
association	401	411
of	413	414
the	416	418
resistance	420	429
with	431	434
the	436	438
mutation	440	447
patterns	449	456
in	458	459
gyrA	461	464
and	466	468
parC	470	473
genes	475	479
,	480	480
as	482	483
is	485	486
currently	488	496
recommended	498	508
by	510	511
the	513	515
Food	517	520
and	522	524
Agriculture	526	536
Organization	538	549
/	550	550
World	551	555
Health	557	562
Organization	564	575
Joint	577	581
Expert	583	588
Committee	590	598
in	600	601
Guidelines	603	612
for	614	616
Evaluation	618	627
of	629	630
Probiotics	632	641
in	643	644
Food	646	649
for	651	653
probiotic	655	663
lactic	665	670
acid	672	675
bacteria	677	684
drug	686	689
resistance	691	700
in	702	703
2001	705	708
.	709	709

The	711	713
Oxford	715	720
Cup	722	724
method	726	731
and	733	735
double	737	742
-	743	743
tube	744	747
dilution	749	756
method	758	763
were	765	768
used	770	773
to	775	776
determine	778	786
the	788	790
quinolone	792	800
resistance	802	811
levels	813	818
of	820	821
the	823	825
isolated	827	834
strains	836	842
.	843	843

Generally	845	853
,	854	854
all	856	858
of	860	861
the	863	865
19	867	868
strains	870	876
showed	878	883
resistance	885	894
towards	896	902
norfloxacin	904	914
and	916	918
ciprofloxacin	920	932
when	934	937
the	939	941
Oxford	943	948
cup	950	952
method	954	959
was	961	963
used	965	968
,	969	969
whereas	971	977
the	979	981
incidence	983	991
was	993	995
lower	997	1001
(	1003	1003
to	1004	1005
norfloxacin	1007	1017
89	1019	1020
.	1021	1021
5	1022	1022
%	1023	1023
and	1025	1027
to	1029	1030
ciprofloxacin	1032	1044
68	1046	1047
.	1048	1048
4	1049	1049
%	1050	1050
)	1051	1051
when	1053	1056
minimum	1058	1064
inhibitory	1066	1075
concentration	1077	1089
breakpoints	1091	1101
(	1103	1103
CLSI	1104	1107
M100	1109	1112
-	1113	1113
S23	1114	1116
)	1117	1117
were	1119	1122
tested	1124	1129
.	1130	1130

Furthermore	1132	1142
,	1143	1143
gene	1145	1148
sequencing	1150	1159
was	1161	1163
conducted	1165	1173
on	1175	1176
gyrA	1178	1181
and	1183	1185
parC	1187	1190
of	1192	1193
topoisomerase	1195	1207
II	1209	1210
of	1212	1213
these	1215	1219
isolated	1221	1228
strains	1230	1236
.	1237	1237

The	1239	1241
genetic	1243	1249
basis	1251	1255
for	1257	1259
quinolone	1261	1269
resistance	1271	1280
may	1282	1284
be	1286	1287
closely	1289	1295
related	1297	1303
to	1305	1306
mutations	1308	1316
in	1318	1319
gyrA	1321	1324
genes	1326	1330
as	1332	1333
there	1335	1339
were	1341	1344
10	1346	1347
mutation	1349	1356
sites	1358	1362
in	1364	1365
amino	1367	1371
-	1372	1372
acid	1373	1376
sequences	1378	1386
encoded	1388	1394
by	1396	1397
gyrA	1399	1402
genes	1404	1408
in	1410	1411
10	1413	1414
quinolone	1416	1424
resistance	1426	1435
strains	1437	1443
and	1445	1447
14	1449	1450
mutation	1452	1459
sites	1461	1465
in	1467	1468
Enterococcus	1470	1481
durans	1483	1488
HZ28	1490	1493
,	1494	1494
whereas	1496	1502
no	1504	1505
typical	1507	1513
mutations	1515	1523
were	1525	1528
detected	1530	1537
in	1539	1540
parC	1542	1545
genes	1547	1551
.	1552	1552
